Editas Medicine

In News

Exclusive: Genetic medicine startup launches to speed programs that stalled at Editas, Biogen - Endpoints News

Endpoints News - Jul 14, 2026

Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving Average - What's Next? - MarketBeat

MarketBeat - Jul 17, 2026

Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT) - Seeking Alpha

Seeking Alpha - May 28, 2026

Editas Medicine to Present New Preclinical Data - GlobeNewswire

GlobeNewswire - Apr 27, 2026

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - Yahoo Finance

Yahoo Finance - Mar 09, 2026

Editas Medicine’s gene-edited therapy reni-cel sees early clinical success - European Pharmaceutical Review

European Pharmaceutical Review - Apr 02, 2026

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - The Motley Fool

The Motley Fool - May 31, 2026

Editas Medicine Announces Promising Preclinical Results for EDIT-401, Showcasing Significant Reductions in LDL-C, Lp(a), and ApoB | EDIT Stock News - Quiver Quantitative

Quiver Quantitative - May 26, 2026

Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options - Stock Titan

Stock Titan - Jun 22, 2026

Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT) - simplywall.st

simplywall.st - May 14, 2026

Editas Medicine Announces Proposed Public Offering - GlobeNewswire

GlobeNewswire - May 26, 2026

Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates - Yahoo Finance

Yahoo Finance - May 11, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment